News Sangamo Therapeutics, Inc.

Equities

SGMO

US8006771062

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-08 pm EDT			5-day change	1st Jan Change
0.5024 ^USD	-6.95%		-7.61%	-7.53%

Mar. 22	Sangamo Therapeutics Prices $24 Million Registered Direct Offering	MT
Mar. 14	Sangamo Therapeutics Pushes Neurology Programs Toward Clinical Development, Wedbush Says	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Sangamo Therapeutics Presents Next-Generation Modular Integrase Technology Engineered to Enable Large-Scale Genome Editing	08:10am	BU
Sangamo Therapeutics : ASGCT 2024	06:47pm	PU
Sangamo Therapeutics : Site-directed integration of large DNA sequences into endogenous sites in the human genome using engineered Modular Integrases (MINTS)	May. 07	PU
Sangamo Therapeutics : Widespread CNS Tau Knockdown for the Potential Treatment of Alzheimer’s Disease and other Tauopathies	May. 07	PU
Sangamo Therapeutics Announces First Quarter 2024 Conference Call and Webcast	May. 02	BU
Sangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data from Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting	Apr. 23	AQ
Sangamo Therapeutics to Present Neurology-Focused Pre-Clinical Data From Its Epigenetic Regulation, Capsid Delivery and Genome Engineering Platforms at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)	Apr. 22	BU
Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering	Mar. 25	AQ
Sangamo Therapeutics Prices $24 Million Registered Direct Offering	Mar. 22	MT
Sangamo Therapeutics Announces Pricing of $24.0 Million Registered Direct Offering	Mar. 22	BU
Sangamo Therapeutics Pushes Neurology Programs Toward Clinical Development, Wedbush Says	Mar. 14	MT
Transcript : Sangamo Therapeutics, Inc., Q4 2023 Earnings Call, Mar 13, 2024	Mar. 13
Sangamo: Q4 Earnings Snapshot	Mar. 13	AQ
Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results	Mar. 13	BU
Sangamo Therapeutics Announces Data From Novel Proprietary Neurotropic AAV Capsid Demonstrating Industry-leading Blood-brain Barrier Penetration and Brain Transduction in NHPs	Mar. 13	BU
Sangamo Therapeutics, Inc. Reports Impairment Results for the Fourth Quarter Ended December 31, 2023	Mar. 13	CI
Sangamo Therapeutics Announces Data from Novel Proprietary Neurotropic Aav Capsid Demonstrating Industry-Leading Blood-Brain Barrier Penetration and Brain Transduction in Nhps	Mar. 13	CI
Sangamo Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Mar. 13	CI
Sangamo Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 13	CI
Sangamo Therapeutics Announces Fourth Quarter and Full Year 2023 Conference Call and Webcast	Mar. 12	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Sangamo Therapeutics, Inc.

Equities

SGMO

US8006771062

Summary

Filters